Neupogen Off-Label Use Complicates Data Extrapolation For Sandoz’s Biosimilar
Executive Summary
Amgen’s biologic is often used off-label in healthy stem cell donors; advisory committee members distinguished between some Neupogen indications in discussing whether extrapolation was appropriate.
You may also be interested in...
Celltrion's Biosimilar Strategy Includes Simultaneous EMA/FDA Reviews
Herceptin and Rituxan biosimilar applications expected to reach FDA early next year while EMA review is ongoing; timing could be another test for 351(k) pathway in US.
Celltrion's Biosimilar Strategy Includes Simultaneous EMA/FDA Reviews
Herceptin and Rituxan biosimilar applications expected to reach FDA early next year while EMA review is ongoing; timing could be another test for 351(k) pathway in US.
FDA Biosimilars Guidances Address Immunogenicity Studies, European Bridge Data, Analytics
The agency’s first three draft guidances on biosimilar product development describe how to characterize biosimilar and reference products and extrapolate data on one condition of use to another. FDA says interchangeability is difficult to determine now and will require a switching study.